基本數據
| LEI | 54930017PANCHC5LYH79 |
| CIK | 1598646 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Minerva Neurosciences, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 4, 2026 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MINERVA NEUROSCIENCES, INC. (a Delaware Corporation) Adopted as of June 3, 2026 ARTICLE I OFFICES AND FISCAL YEAR SECTION 1.01. Registered Office. The registered office of the corporation shall be Corporation Service Company, 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, State of Delaware until otherwise established by |
|
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| June 4, 2026 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERVA NEUROSCIENCES, INC. Minerva Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Minerva Neurosciences, Inc. The |
|
| May 27, 2026 |
Up to $75,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-294203 PROSPECTUS SUPPLEMENT (To Prospectus dated March 19, 2026) Up to $75,000,000 Common Stock We entered into a sales agreement dated May 27, 2026 (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”, or the “Agent”), relating to the issuance and sale of shares of our common stock, $0.0001 par value p |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2026 |
Minerva Neurosciences, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT EX-1.1 Exhibit 1.1 Minerva Neurosciences, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 27, 2026 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
|
| May 5, 2026 |
EX-99.1 Exhibit 99.1 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only lat |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 23, 2026 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2026 |
DEFA14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| April 10, 2026 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| April 2, 2026 |
EX-10.2 Exhibit 10.2 CONSULTANCY AGREEMENT (1) MINERVA NEUROSCIENCES, INC. (2) GEOFF RACE CONTENTS Clause Page 1. Interpretation 1 2. Term of engagement 3 3. Duties and obligations 3 4. Fees 5 5. Expenses 6 6. Share options 6 7. Other activities 6 8. Confidential information 6 9. Data protection 7 10. Intellectual property 7 11. Insurance and liability 9 12. Termination 9 13. Obligations on termin |
|
| April 2, 2026 |
EX-99.1 Exhibit 99.1 Minerva Announces Leadership Transition Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 2, 2026 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the app |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| April 2, 2026 |
DATED 30 MARCH 2026 SETTLEMENT AGREEMENT MIND-NRG SARL MINERVA NEUROSCIENCES, INC. GEOFF RACE EX-10.1 Exhibit 10.1 DATED 30 MARCH 2026 SETTLEMENT AGREEMENT between MIND-NRG SARL and MINERVA NEUROSCIENCES, INC. and GEOFF RACE CONTENTS CLAUSE 1. Interpretation 3 2. Arrangements on termination 4 3. Termination payment 5 4. Options and PRSUs 6 5. Legal fees 6 6. Waiver of claims 6 7. Employee indemnities 8 8. Company property and information 9 9. Employee warranties and acknowledgments 9 10. R |
|
| March 17, 2026 |
CORRESP March 17, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren S. Hamill Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333-294203 Acceleration Request Requested Date: March 19, 2026 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: In acco |
|
| March 16, 2026 |
March 16, 2026 Remy Luthringer Chief Executive Officer Minerva Neurosciences, Inc. |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction (Commission (IRS Employer |
|
| March 11, 2026 |
Calculation of Filing Fee Tables S-3 Minerva Neurosciences, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| March 11, 2026 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is a summary, does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the applicable provisions of Delaware law and our amended and restated certificate of incorporation and our am |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| March 11, 2026 |
As filed with the Securities and Exchange Commission on March 11, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 11, 2026 Registration No. |
|
| March 11, 2026 |
EX-4.9 Exhibit 4.9 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associatio |
|
| March 11, 2026 |
Exhibit 10.10 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Last amended on December 22, 2025 (the “Amendment Date”) Cash Compensation Effective as of January 1, 2026, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer as summarized below. The Lead Independent Director, chairpersons of |
|
| March 11, 2026 |
EX-4.10 Exhibit 4.10 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associat |
|
| March 11, 2026 |
EX-99.1 Exhibit 99.1 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass.– March 11, 2026 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-sta |
|
| March 11, 2026 |
EX-4.8 Exhibit 4.8 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi |
|
| March 11, 2026 |
EX-4.6 Exhibit 4.6 MINERVA NEUROSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 4 Section 1.01 Definitions of Terms 4 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 7 Section 2.01 Designation and Terms of Securities 7 Section 2.02 Form of Securities and Trustee’s Certif |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| January 6, 2026 |
94,600,000 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-292410 PROSPECTUS 94,600,000 Shares of Common Stock This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus, including their pledgees, donees, transferees, assignees, successors, designees or their respective success |
|
| January 2, 2026 |
CORRESP January 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333-292410 Acceleration Request Requested Date: January 6, 2026 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: In acc |
|
| December 31, 2025 |
December 31, 2025 Remy Luthringer Chief Executive Officer and Chairman of the Board of Directors Minerva Neurosciences, Inc. |
|
| December 23, 2025 |
EX-3.3 Exhibit 3.3 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERVA NEUROSCIENCES, INC. Minerva Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Minerva Neurosciences, Inc. The |
|
| December 23, 2025 |
As filed with the Securities and Exchange Commission on December 23, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 23, 2025 Registration No. |
|
| December 23, 2025 |
Calculation of Filing Fee Tables S-3 Minerva Neurosciences, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| December 23, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Minerva Neurosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 667,639 $ 3.968 $ 2,649,191.55 0.0001381 $ 365.85 2 Equit |
|
| December 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on December 23, 2025 S-8 As filed with the U.S. Securities and Exchange Commission on December 23, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Minerva Neurosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 26-0784194 (State or other jurisdiction of Incorporation or orga |
|
| December 22, 2025 |
EX-10.1 Exhibit 10.1 MINERVA NEUROSCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN ADOPTED BY BOARD OF DIRECTORS ON: DECEMBER 19, 2013 APPROVED BY THE STOCKHOLDERS ON: DECEMBER 19, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 29, 2014 AMENDMENT AND RESTATEMENT APPROVED BY THE STOCKHOLDERS ON: JUNE 2, 2014 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 21, 2 |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| November 24, 2025 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 19, 2025 |
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors EX-99.1 Exhibit 99.1 Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors BURLINGTON, Mass. – November 19, 2025 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| November 19, 2025 |
EX-10.1 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) by and between Minerva Neurosciences, Inc (“Client”) and Inderjit Kaul, (“Consultant”) is effective as of November 14, 2025 (the “Effective Date”). RECITALS WHEREAS the Consultant is being appointed as a member of the Client’s Board of Directors (the “Board”) and in connection with that role, remains eligible to |
|
| November 14, 2025 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| October 22, 2025 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved • Minerva secures $80 million up front and up to an additional |
|
| October 22, 2025 |
EX-4.1 Exhibit 4.1 MINERVA NEUROSCIENCES, INC. TRANCHE A WARRANT TO PURCHASE SERIES A PREFERRED STOCK Warrant No.: A- Number of Warrant Shares: Date of Issuance: October [ ], 2025 (“Issuance Date”) Expiration Date: The tenth day following the date of the Company’s public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial |
|
| October 22, 2025 |
EX-4.2 Exhibit 4.2 MINERVA NEUROSCIENCES, INC. TRANCHE B WARRANT TO PURCHASE SERIES A PREFERRED STOCK Warrant No.: B- Number of Warrant Shares: Date of Issuance: October [], 2025 (“Issuance Date”) Expiration Date: The four (4)-year anniversary of the Issuance Date (“Expiration Date”). Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), certifies that, for good and valuable conside |
|
| October 22, 2025 |
EX-10.2 Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of October 21, 2025, is made by and between Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), and the undersigned holder of shares of the Company (the “Investor”). The Company and the Investor shall be referred to herein from time to time collectively as the “Parties.” Capitalized terms us |
|
| October 22, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 21, 2025, by and between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively with any other purchaser, acting severally |
|
| October 22, 2025 |
EX-3.1 Exhibit 3.1 MINERVA NEUROSCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) d |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 21, 2025 |
Amended and Restated Non-Employee Director Compensation Plan Exhibit 10.12 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 Last approved on December 5, 2024, effective as of January 1, 2025 (the “Effective Date”) Cash Compensation Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annu |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2025 |
Statement of Company Policy on Insider Trading and Disclosure Exhibit 19.1 Minerva Neurosciences, Inc. Insider Trading Policy (adopted February 20, 2025) Introduction During the course of your relationship with Minerva Neurosciences, Inc. (“Minerva”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Minerva or other publicly traded companies that Minerva has business relationships with. Material |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2024 |
NERV / Minerva Neurosciences, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 MINERVA NEUROSCIENCES INC COMMON STOCK Cusip #603380205 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #603380205 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11 |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| October 22, 2024 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2023 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 FORTHETRANSITIONPERIODFROMTO CommissionFileNumber001-36517 MinervaNeurosciences,Inc. (ExactnameofRegistrantasspecifiedinitsCh |
|
| October 22, 2024 |
DEFA14A 1 d843316ddefa14a.htm DEFA14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definiti |
|
| October 22, 2024 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| April 22, 2024 |
Amended and Restated Non-Employee Director Compensation Plan Exhibit 10.12 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 Last approved on November 29, 2023, effective as of January 1, 2024 (the “Effective Date”) Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2024 |
Exhibit 99.1 Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia BURLINGTON, Mass., – February 27, 2024 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File N |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 22, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97 Minerva Neurosciences, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po |
|
| February 9, 2024 |
US6033802058 / Minerva Neurosciences Inc / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 MINERVA NEUROSCIENCES INC COMMON STOCK Cusip #603380205 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #603380205 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 491,746 Item 6: 0 Item 7: 491,746 Item 8: 0 Item 9: |
|
| January 18, 2024 |
US6033802058 / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 nerv1573-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380205 (CUSIP Number) December 31, 2023 (Date of |
|
| November 7, 2023 |
Amended and Restated Non-Employee Director Compensation Plan EXHIBIT 10.1 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN Approved: March 7, 2018 Effective: April 1, 2018 As amended as of July 30, 2023 (the “Effective Date”) Effective as of the Effective Date, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) will receive an annual cash retainer of $35,000, the Lead Independent Direc |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| November 7, 2023 |
Amended and Restated 2013 Equity Incentive Plan EXHIBIT 10.2 Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by Board of Directors on: December 19, 2013 Approved by the Stockholders on: December 19, 2013 Amended and Restated by the Board of Directors on: April 29, 2014 Amendment and Restatement Approved by the Stockholders on: June 2, 2014 Amended and restated by the Board of Directors on: April 21, 2018 Amen |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2023 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 15, 2023 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934 ForthefiscalyearendedDecember31,2022 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGE ACTOF1934FORTHETRANSITIONPERIODFROMTO CommissionFileNumber001-36517 MinervaNeurosciences,Inc. (ExactnameofRegistrantasspecifiedinitsC |
|
| August 15, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2023 |
Up to 2,000,575 Shares of Common Stock Offered by the Selling Stockholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-273686 PROSPECTUS Up to 2,000,575 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the resale from time to time of up to 2,000,575 shares of common stock, par value $0.0001 per share, of Minerva Neurosciences, Inc. (the “Common Stock”) by the selling stockholders listed on page 9 (the “S |
|
| August 7, 2023 |
August 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333-273686 Acceleration Request Requested Date: August 9, 2023 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under |
|
| August 7, 2023 |
United States securities and exchange commission logo August 7, 2023 Remy Luthringer Chief Executive Officer Minerva Neurosciences, Inc. |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Minerva Neurosciences, Inc. |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| July 7, 2023 |
NERV / Minerva Neurosciences Inc / Boehringer AG - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603380106 (CUSIP Number) Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein, Germany Attention: Head of Corp. Legal |
|
| July 7, 2023 |
Joint Filing Agreement among Boehringer AG and Boehringer Ingelheim International GmbH. EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| June 28, 2023 |
Form of Pre-Funded Warrant (June 2023) EX-4.1 Exhibit 4.1 Execution Version FORM OF PRE-FUNDED WARRANT NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYP |
|
| June 28, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 27, 2023, is made by and among MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. |
|
| June 28, 2023 |
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market Exhibit 99.1 Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market BURLINGTON, Mass., – June 28, 2023 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2023 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FDA grants appeal and files NDA BURLINGTON, Mass. – May 1, 2023 – (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous sy |
|
| May 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-36517 26-0784194 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| March 8, 2023 |
Exhibit 10.30 SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER This Second Amendment to the Employment Agreement Of Remy Luthringer (the “Amendment”) is entered into this 6th day of March 2023 (the “Effective Date”), by and between Remy Luthringer (the “Employee”) and Mind-NRG SARL (the “Company”). Recitals A. The Company and the Employee have entered into that certain Employment Ag |
|
| March 8, 2023 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Minerva Neurosciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of our common stock is a summary, does not purport to b |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Minerva Neurosciences, Inc. (Tit |
|
| February 9, 2023 |
US6033802058 / Minerva Neurosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380205 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 1, 2023 |
US6033802058 / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380205 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing o |
|
| December 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| December 28, 2022 |
Exhibit 99.1 Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass. ? December 28, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today an |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| December 16, 2022 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF REMY LUTHRINGER (the ?Amendment?) is entered into this 13th day of December 2022 (the ?Effective Date?), by and between REMY LUTHRINGER (the ?Employee?) and Mind-NRG SARL (the ?Company?). RECITALS A. The Company and the Employee have entered into that ce |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neuroscien |
|
| October 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| October 17, 2022 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass. – October 17, 2022 – (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat |
|
| September 21, 2022 |
September 21, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 File No. 333- 267424 Acceleration Request Requested Date: September 23, 2022 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 |
|
| September 21, 2022 |
United States securities and exchange commission logo September 21, 2022 Remy Luthringer, Ph. |
|
| September 21, 2022 |
United States securities and exchange commission logo September 21, 2022 Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. |
|
| September 14, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga |
|
| September 14, 2022 |
Power of Attorney (included on the signature page) Table of Contents As filed with the Securities and Exchange Commission on September 14, 2022 Registration No. |
|
| September 14, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Minerva Neurosciences, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s |
|
| September 14, 2022 |
MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington, MA 01803 CORRESP 1 filename1.htm MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington, MA 01803 September 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Julie Sherman Brian Cascio Re: Minerva Neurosciences, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2021 |
|
| September 14, 2022 |
Exhibit 4.4 MINERVA NEUROSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 |
|
| September 14, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and |
|
| September 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Minerva Neurosciences, Inc. |
|
| September 14, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 MINERVA NEUROSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MINERVA NEUROSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga |
|
| September 12, 2022 |
United States securities and exchange commission logo September 12, 2022 Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. |
|
| September 9, 2022 |
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market Exhibit 99.1 Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market BURLINGTON, Mass. ? September 9, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported a listing transfer from The Nasdaq Global Market to The Nasdaq Ca |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| August 23, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| August 23, 2022 |
NERV / Minerva Neurosciences Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Minerva Neurosciences, Inc. (Title of Class of Securities) Common Stock, $0.0001 Par V |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| August 22, 2022 |
Exhibit 99.1 Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia WALTHAM, Mass. ? August 22, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announce |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, |
|
| June 17, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERVA NEUROSCIENCES, INC. Minerva Neurosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of the Corporation is Minerva Neurosciences, Inc. The Certifi |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36517 26-0784194 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q sel f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| April 26, 2022 |
DEF 14A 1 d247036ddef14a.htm DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 26, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2022 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 13, 2022 |
Roluperidone Update Webcast: Wednesday, April 13, 2022, at 11:00 ET To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2489714. |
|
| April 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| April 7, 2022 |
Exhibit 99.1 Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Company to Host Webcast Wednesday, April 13, 2022 at 11am ET WALTHAM, Mass., April 7, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage |
|
| March 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commissi |
|
| March 1, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 24, 2022, Minerva Neurosciences, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description of our common stock is a summa |
|
| March 1, 2022 |
Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| February 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| February 28, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia WALTHAM, Mass. ? February 28, 2022 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage |
|
| February 14, 2022 |
NERV / Minerva Neurosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing o |
|
| February 11, 2022 |
NERV / Minerva Neurosciences Inc / Luthringer Remy - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 10, 2022 |
NERV / Minerva Neurosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| January 5, 2022 |
Corporate Presentation January 2022 Exhibit 99.1 Forward-Looking Statement Safe-Harbor Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management?s expectations as of the date of this presentation, and involve certain risks and uncertainties. Forward-looking statements incl |
|
| December 8, 2021 |
3 Authors: Michael Davidson1,2 MD, Jay Saoud1 PhD, Corinne Staner3 MD, Nadine Noel3 PhD, ?Sandra Werner3 PhD, Elisabeth Luthringer3 RN, Philip Harvey PhD, Gregory Strauss PhD, Mark Weiser4MD, Remy Luthringer1 PhD Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia Study registration: Eudra-CT: 2017-003333-29; NCT03397134 Affiliations: (1) Minerva Neurosciences; (2) Nicosia University Medical School; (3) PPRS, (4) University of Tel Aviv School of Medicine (6) University of Miami Miller School of Medicine (7) University of Georgia Minerva Neurosciences is the sponsor of the trials Exhibit 99. |
|
| December 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MINERVA NEUROSCIENCES INC (Name of Issuer) Common shares (Title of Class of Securities) 603380 106 (CUSIP Number) 23 November 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 24, 2021 |
SC 13G 1 Schedule13G.txt UNTERSCHREITUNG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MINERVA NEUROSCIENCES INC (Name of Issuer) Common shares (Title of Class of Securities) 603380 106 (CUSIP Number) 24 November 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| November 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 3, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission Waltham, Mass. ? November 3, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceut |
|
| October 12, 2021 |
Exhibit 10.2 October 11th, 2021 Fred Ahlholm 48 Hawkins Lane North Andover, MA 01842 Re: Amended and Restated Employment Agreement Dear Fred, Minerva Neurosciences, Inc. (the ?Company?) is pleased to offer you continued employment on the terms set forth in this letter agreement (the ?Agreement?). 1. Employment. This Agreement replaces and supersedes the May 30, 2014 and the August 1, 2016 offer le |
|
| October 12, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF GEOFF RACE This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF GEOFF RACE (the ?Amendment?) is entered into this 11th day of October 2021 (the ?Effective Date?), by and between GEOFF RACE (the ?Employee?) and Mind-NRG SARL (the ?Company?). RECITALS A. The Company and the Employee have entered into that certain Employment Agreement effecti |
|
| October 12, 2021 |
Exhibit 99.1 Minerva Neurosciences Announces Promotion of Geoff Race to President Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA Waltham, Mass. ? October 11, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| September 30, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Waltham, Mass. ? September 30, 2021 ? (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq |
|
| September 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| September 8, 2021 |
Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF DR. RAMANA KUCHIBHATLA AS SENIOR VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| September 8, 2021 |
Exhibit 10.1 September 2, 2021 Jay B. Saoud 271 Pepperell Road Groton, MA 01450 Re: Transition, Separation, and Consulting Agreement Dear Jay: This letter sets forth the terms of the transition, separation, and consulting agreement (the ?Agreement?) that Minerva Neurosciences, Inc. (the ?Company?) is offering to you to aid in your transition. 1. SEPARATION DATE. In connection with your decision to |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No.2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 603 |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 60 |
|
| August 2, 2021 |
Exhibit (a)(1)(A) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 02451 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS JULY 6, 2021 MINERVA NEUROSCIENCES, INC. SUMMARY TERM SHEET ? OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS This offer and withdrawal rights will expire at 5:00 p.m., Eastern Time, on Tuesday, August 3, 2021, unl |
|
| July 12, 2021 |
NERV / Minerva Neurosciences Inc / BlackRock Inc. Passive Investment us6033801068071021.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) MINERVA NEUROSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 603380106 - (CUSIP Number) June 30, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| July 6, 2021 |
Notice of Withdrawal of Election Form EX-99.A1D 5 d54260dex99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by Minerva Neurosciences, Inc. (“Minerva”) to exchange some or all of your outstanding Eligible Options for New Restricted Stock Units, subject to the terms and conditions of the Offer to Exchange Eligible Options for New Restricted St |
|
| July 6, 2021 |
Form of Email to Eligible Holders Confirming Acceptance of Eligible Options Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE HOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: Minerva Neurosciences, Inc. |
|
| July 6, 2021 |
Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer EX-99.A1G 8 d54260dex99a1g.htm EX-99.(A)(1)(G) Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: Minerva Neurosciences, Inc. Re: REMINDER – Offer to Exchange Eligible Options for New Restricted Stock Units This email serves as a reminder that we are nearing the expiration of the Exchange Offer described in the Offer to Exchange Eligib |
|
| July 6, 2021 |
Form of Email Confirming Receipt of Election Form EX-99.A1E 6 d54260dex99a1e.htm EX-99.(A)(1)(E) Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: Minerva Neurosciences, Inc. Re: Confirmation of Receipt of Election Form This message confirms that Minerva Neurosciences, Inc. (“Minerva”) has received your Election Form. This confirmation should not, however, be construed to imply that the Election Form you submitted has been |
|
| July 6, 2021 |
Offer to Exchange Eligible Options for New Restricted Stock Units, dated July 6, 2021 EX-99.A1A 2 d54260dex99a1a.htm EX-99.(A)(1)(A) Exhibit (a)(1)(A) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 02451 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS JULY 6, 2021 MINERVA NEUROSCIENCES, INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS This offer and withdrawal rights will expire at 5:00 p.m. |
|
| July 6, 2021 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election Form EX-99.A1F 7 d54260dex99a1f.htm EX-99.(A)(1)(F) Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: Minerva Neurosciences, Inc. Re: Confirmation of Receipt of Notice of Withdrawal of Election Form This message confirms that Minerva Neurosciences, Inc. (“Minerva”) has received your Notice of Withdrawal of Election Form (“Notice of Withdrawal”). This conf |
|
| July 6, 2021 |
Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: Minerva Neurosciences, Inc. |
|
| July 6, 2021 |
Form of Announcement Email to Eligible Holders EX-99.A1B 3 d54260dex99a1b.htm EX-99.(A)(1)(B) Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE HOLDERS Subject: Minerva Neurosciences, Inc. Offer to Exchange Eligible Options for New Restricted Stock Units To: All Eligible Holders Date: July 6, 2021 We are pleased to announce that Minerva Neurosciences, Inc. (“Minerva,” “we,” “us” or “our”) is commencing an Offer to Exchange Eligible Opti |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MINERVA NEUROSCIENCES, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 603380106 (CUSIP Numbe |
|
| July 6, 2021 |
Form of Expiration Notice Email EX-99.A1J 11 d54260dex99a1j.htm EX-99.(A)(1)(J) Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: Minerva Neurosciences, Inc. Re: Expiration of the Exchange Offer The Exchange Offer described in the Offer to Exchange Eligible Options for New Restricted Stock Units, dated July 6, 2021 (the “Offer Documents”), has expired, and no additional Election Forms or Notices of Withdrawal may be submit |
|
| July 6, 2021 |
Exhibit (a)(1)(C) MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286 WALTHAM, MA 0245 OPTION EXCHANGE – ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON TUESDAY, AUGUST 3, 2021, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, including (1) the Offer to Exchan |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36517 26-0784194 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2021 |
Form of Supplemental Retention Benefits Letter Agreement for Other Officers EXHIBIT 10.3 EXHIBIT 10.3Form of Executive Supplemental Retention Benefits Letter Agreement April 27, 2021 Re:Supplemental Retention Benefit Dear : You will recall that last year the Compensation Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Minerva Neurosciences, Inc. (the ?Company?) adopted a retention program for certain of its key employees, pursuant to which the Compa |
|
| May 12, 2021 |
Geoff Race Supplemental Retention Benefits Letter Agreement (redacted) EX-10.2 3 nerv-ex102184.htm EX-10.2 EXHIBIT 10.2 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.2Geoff Race Supplemental Retention Benefits Letter Agreement (redacted) April 27, 2021 Geoff Race [•••] Re:Supplemental Retention Benefit D |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| May 12, 2021 |
Remy Luthringer Supplemental Retention Benefits Letter Agreement (redacted) EX-10.1 2 nerv-ex101185.htm EX-10.1 EXHIBIT 10.1 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.1Remy Luthringer Supplemental Retention Benefits Letter Agreement (redacted) April 27, 2021 Remy Luthringer, PhD [•••] Re:Supplemental Rete |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commiss |
|
| March 8, 2021 |
EX-10.48 3 nerv-ex1048189.htm EX-10.48 Exhibit 10.48 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.48 Royalty Purchase Agreement (redacted) Execution Copy Royalty Purchase Agreement By and Between Minerva Neurosciences, Inc. and RPI 2 |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosc |
|
| March 8, 2021 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. EX-4.4 2 nerv-ex449.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 4, 2021, Minerva Neurosciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of |
|
| March 8, 2021 |
EX-21.1 4 nerv-ex2117.htm EX-21.1 Exhibit 21.1 Subsidiaries of Minerva Neurosciences, Inc. Name Jurisdiction of Incorporation Mind-NRG Sarl Switzerland Minerva Neurosciences Securities Corporation Massachusetts |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Minerva Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7*) MINERVA NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 603380106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing o |
|
| February 10, 2021 |
SC 13G 1 tv01401-minervaneurosciences.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule p |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Minerva Neurosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 603380106 Date of Event Which Requires Filing of this Statement: January 29, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 8, 2021 |
SCHEDULE 13G Amendment No. 6 MINERVA NEUROSCIENCES INC COMMON STOCK Cusip #603380106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #603380106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,000 Item 6: 0 Item 7: 395,479 Item 8: 0 Item 9: 395,479 Item 11: 0.9 |
|
| January 29, 2021 |
us6033801068012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) MINERVA NEUROSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 603380106 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 19, 2021 |
MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION EX-99.1 2 d945121dex991.htm EX-99.1 Exhibit 99.1 Contact: William B. Boni Minerva Neurosciences, Inc. (617) 600-7376 Royalty Pharma plc (212) 883-2295 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION Waltham, MA and New York, NY, January 19, 2021 – Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RP |
|
| January 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| December 1, 2020 |
Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone Waltham, MA, December 1, 2020 – Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the d |
|
| December 1, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2020 |
Michael Davidson Retention Benefits Letter Agreement (redacted EXHIBIT 10.7 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.7Michael Davidson Retention Benefits Letter Agreement (redacted) Michael Davidson [•••] Re:Retention Benefits Dear Michael: In recognition of the importance of your services t |
|
| November 2, 2020 |
Jay Saoud Retention Benefits Letter Agreement (redacted) EXHIBIT 10.3 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.3Jay Saoud Retention Benefits Letter Agreement (redacted) October 13, 2020 Jay B. Saoud [•••] Re:Retention Benefits Dear Jay: In recognition of the importance of your services |
|
| November 2, 2020 |
Geoff Race Retention Benefits Letter Agreement (redacted EXHIBIT 10.2 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.2Geoff Race Retention Benefits Letter Agreement (redacted) October 13, 2020 Geoff Race [•••] Re:Retention Benefits Dear Geoff: In recognition of the importance of your service |
|
| November 2, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neuroscien |
|
| November 2, 2020 |
Remy Luthringer Retention Benefits Letter Agreement (redacted) EXHIBIT 10.1 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.1Remy Luthringer Retention Benefits Letter Agreement (redacted) October 13, 2020 Remy Luthringer, PhD [•••] Re:Retention Benefits Dear Remy: In recognition of the importance o |
|
| November 2, 2020 |
Frederick Ahlholm Retention Benefits Letter Agreement (redacted) EXHIBIT 10.5 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.5Frederick Ahlholm Retention Benefits Letter Agreement (redacted) October 13, 2020 Frederick Ahlholm [•••] Re:Retention Benefits Dear Fred: In recognition of the importance of |
|
| November 2, 2020 |
Joseph Reilly Retention Benefits Letter Agreement (redacted) EX-10.6 7 nerv-ex106173.htm EX-10.6 EXHIBIT 10.6 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.6Joseph Reilly Retention Benefits Letter Agreement (redacted) October 13, 2020 Joseph Reilly [•••] Re:Retention Benefits Dear Joe: In recog |
|
| November 2, 2020 |
Devin Smith Retention Benefits Letter Agreement (redacted EXHIBIT 10.4 Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXHIBIT 10.4Devin Smith Retention Benefits Letter Agreement (redacted) October 13, 2020 Devin Smith [•••] Re:Retention Benefits Dear Devin: In recognition of the importance of your servi |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commis |
|
| September 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 3, 2020 |
Amended and Restated 2013 Equity Incentive Plan EX-10.3 3 nerv-ex103210.htm EX-10.3 EXHIBIT 10.3 Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by Board of Directors on: December 19, 2013 Approved by the Stockholders on: December 19, 2013 Amended and Restated by the Board of Directors on: April 29, 2014 Amendment and Restatement Approved by the Stockholders on: June 2, 2014 Amended and restated by the Board |
|
| August 3, 2020 |
EX-10.2 2 nerv-ex102120.htm EX-10.2 EXHIBIT 10.2 Certain information identified with brackets (“[***]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL SETTLEMENT AGREEMENT WHEREAS, Janssen Pharmaceutica, N.V. (“Janssen”) and Minerva Neurosciences, Inc. (“Minerva”) are parties (together, the “Partie |
|
| August 3, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| July 2, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| July 1, 2020 |
MINERVA NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTOREXANT (MIN-202) EX-99.1 2 d947910dex991.htm EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTOREXANT (MIN-202) • Preserves royalties payable to Minerva on worldwide sales of seltorexant • Eliminates all financial obligations w |
|
| July 1, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Comm |
|
| June 25, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36517 (Commission File |
|
| June 5, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| June 5, 2020 |
EX-99.1 ROLUPERIDONE: Topline results from the Phase 3 trial: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 40-Week Open-Label Extension June 5th, 2020 : NERV Exhibit 99.1 Forward-Looking Statement Safe-Harb |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Commi |
|
| May 29, 2020 |
EX-99.1 Exhibit 99.1 Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF ROLUPERIDONE (MIN-101) FOR TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA • The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the p |
|
| May 4, 2020 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, |
|
| April 28, 2020 |
DEFA14A 1 d860861ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 28, 2020 |
DEF 14A 1 d860861ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| April 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction of incorporation) (Com |
|
| April 1, 2020 |
EX-99.1 Roluperidone: A potential novel mechanism to treat the negative symptoms of schizophrenia William Carpenter MD John Kane MD Steven Marder MD Ofer Agid MD Remy Luthringer PhD Hosted by Minerva Neurosciences (Nasdaq: NERV) Tuesday, March 31, 2020 Exhibit 99.1 All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Look |
